Meeting
2018 Genitourinary Cancers Symposium
Active surveillance in prostate cancer patients: Modeling upgrading and upsizing at 1 year rebiopsy.
Authors
Nicola Nicolai
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Nicola Nicolai , MariaFrancesca Alvisi , Tiziana Rancati , Barbara Avuzzi , Fabio Badenchini , Mario Catanzaro , Maurizio Colecchia , Teresa Di Florio , Tiziana Magnani , Cristina Marenghi , Sara Morlino , Barbara Noris Chiorda , Biagio Paolini , Silvia Stagni , Antonio Tesone , Tullio Torelli , Sergio Villa , Nadia Zaffaroni , Roberto Salvioni , Riccardo Valdagni
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Localized Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 90)
DOI
10.1200/JCO.2018.36.6_suppl.90
Abstract #
90
Poster Bd #
E10
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
The accuracy of multiparametric magnetic resonance imaging (mpMRI) using PI-RADS v2 in disease upgrading on re-biopsy among patients with low-risk prostate cancer (PCa) on active surveillance (AS): A Brazilian perspective.
First Author: Públio C. C. Viana
Poster
2024 ASCO Genitourinary Cancers Symposium
Safety and clinical validity of tumor genomic testing for guiding active surveillance selection in men with NCCN intermediate-risk prostate cancer.
First Author: Lauren Lenz
Poster
2021 Genitourinary Cancers Symposium
p2PSA-associated parameters are significant predictors of reclassification of first-year protocol biopsy on active surveillance for early-stage prostate cancer patients: From the PRIAS-JAPAN study.
First Author: Takuma Kato
Poster
2021 Genitourinary Cancers Symposium
PSA velocity to predict clinical progression in African American and non-Hispanic White patients with low-risk prostate cancer undergoing active surveillance.
First Author: Juan Javier-Desloges